Maximize insights with multimodal sequencing
Why choose QIAseq Multimodal technology?
Recent advances in NGS and bioinformatics have empowered researchers to efficiently interrogate DNA and RNA modifications in biological samples. However, current approaches require two separate workflows for DNA and RNA library preparation, each with inherent bias. Having different workflows increases costs and turnaround times, ultimately delaying the acquisition of actionable data. Limited sample availability can also impact your ability to achieve comprehensive genomic and transcriptomic insights.
One sample, one workflow and one day is all you need
Maximize the information you derive from a single total nucleic acid sample by simultaneously profiling DNA and RNA biomarkers in one consolidated workflow and just one day. With QIAseq Multimodal technology, you can interrogate various biomarkers in the same, single-day workflow from as little as 10 ng of sample.
Dr. Vincent Funari, Vice President of Research and Development at NeoGenomics Laboratories
Go from sample to sequencing in a day
Achieve high-confidence data
- Detect rare variants
- Reduce index hopping and read mis-assignment
Get complete coverage
- Find known and novel fusions
- Cover GC-rich regions
- Superior customization
Save sample, time and costs
- Multiple insights from a single extraction and workflow
- Reduce turnaround time and costs by 50%
Comprehensive genomic profiling
Comprehensive genomic profiling (CGP) is dramatically changing our understanding of various cancers, revealing an unprecedented level of detail. Multimodal sequencing can accelerate this rapidly evolving field of research.
Top 3 reasons to adopt a multimodal approach for CGP:
- Save time and resources: Consolidate separate workflows into a single-day, sample to sequencing workflow.
- Conserve precious samples: Simultaneously profile multiple DNA and RNA biomarkers, TMB and MSI from a single, low-input sample.
- Get deeper insights: Achieve a holistic view of various cancer biomarkers efficiently.
Profiling of DNA variants in solid and hematologic malignancies
QIAseq: Covers exonic regions +5–10 bases of exon/intron junctions
A hybrid gene formed from two previously discrete genes, implicated in tumorigenesis
QIAseq: Targets transcripts in COSMIC, covers exons in both 3’ and 5’ directions
Tumor mutational burden
The measure of the number of mutations found within a tumor, which can indicate treatment response
QIAseq: Coverage of >1 Mb enables statistically significant assessment of TMB
Microsatellite instability status
Changes in microsatellites, or repeat regions, associated with various cancers
QIAseq: 26 loci with well-established utility for correlation to treatment response
Explore the QIAseq Pan-cancer Multimodal Panel